These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18065924)

  • 41. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: a primer for radiologists.
    Prasad SR; Jagirdar J
    J Comput Assist Tomogr; 2008; 32(1):1-3. PubMed ID: 18303280
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor.
    Moreno-Romero JA; Segura S; Mascaró JM; Cowper SE; Julià M; Poch E; Botey A; Herrero C
    Br J Dermatol; 2007 Oct; 157(4):783-7. PubMed ID: 17627792
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adverse Reactions to Gadoterate Meglumine: Review of Over 25 Years of Clinical Use and More Than 50 Million Doses.
    de Kerviler E; Maravilla K; Meder JF; Naggara O; Dubourdieu C; Jullien V; Desché P
    Invest Radiol; 2016 Sep; 51(9):544-51. PubMed ID: 27504794
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the safety and efficacy of gadoteridol injection (a low osmolal magnetic resonance contrast agent). Clinical trials report.
    DeSimone D; Morris M; Rhoda C; Lucas T; Zielonka J; Olukotun A; Carvlin M
    Invest Radiol; 1991 Nov; 26 Suppl 1():S212-6; discussion S232-5. PubMed ID: 1808133
    [No Abstract]   [Full Text] [Related]  

  • 45. Severe adverse reaction to iv gadopentetate dimeglumine.
    Takebayashi S; Sugiyama M; Nagase M; Matsubara S
    AJR Am J Roentgenol; 1993 Mar; 160(3):659. PubMed ID: 8430574
    [No Abstract]   [Full Text] [Related]  

  • 46. Renal tolerance of gadolinium-DOTA and gadolinium-DTPA in rats.
    Brillet G; Dubois M; Beaufils H; Bourbouze R; Deray G
    Invest Radiol; 1994 Mar; 29(3):352-4. PubMed ID: 8175311
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hair and fingernail gadolinium ICP-MS contents in an overdose case associated with nephrogenic systemic fibrosis.
    Saussereau E; Lacroix C; Cattaneo A; Mahieu L; Goulle JP
    Forensic Sci Int; 2008 Mar; 176(1):54-7. PubMed ID: 17983714
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dosage of gadoteridol and adverse reactions relative to gadopentetate.
    Hieronim DE; Kanal E; Swanson DP
    Am J Health Syst Pharm; 1995 Nov; 52(22):2556-9. PubMed ID: 8590239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A word of caution on the use of high-dose MR contrast media in patients with renal failure.
    Geckeis K; Eggebrecht H; Quick HH; Barkhausen J; Kribben A; Erbel R
    J Endovasc Ther; 2005 Apr; 12(2):262. PubMed ID: 15823076
    [No Abstract]   [Full Text] [Related]  

  • 50. Eye and testicular pain after administration of gadopentetate dimeglumine.
    Padhani AR; Lopez AJ; Revell PB; MacVicar DA
    AJR Am J Roentgenol; 1995 Aug; 165(2):484-5. PubMed ID: 7618587
    [No Abstract]   [Full Text] [Related]  

  • 51. Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency.
    Chewning RH; Murphy KJ
    J Vasc Interv Radiol; 2007 Mar; 18(3):331-3. PubMed ID: 17377176
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acute side effects of three commonly used gadolinium contrast agents in the paediatric population.
    Neeley C; Moritz M; Brown JJ; Zhou Y
    Br J Radiol; 2016 Jul; 89(1063):20160027. PubMed ID: 27194459
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of contrast media for magnetic resonance imaging.
    Goldstein HA; Wiggins JR; Kashanian F
    Ann N Y Acad Sci; 1992 Mar; 649():322-31. PubMed ID: 1580503
    [No Abstract]   [Full Text] [Related]  

  • 54. Life-threatening anaphylactoid reaction after iv injection of gadoterate meglumine.
    Meuli RA; Maeder P
    AJR Am J Roentgenol; 1996 Mar; 166(3):729. PubMed ID: 8623674
    [No Abstract]   [Full Text] [Related]  

  • 55. Nephrogenic systemic fibrosis: a chemical perspective.
    Rofsky NM; Sherry AD; Lenkinski RE
    Radiology; 2008 Jun; 247(3):608-12. PubMed ID: 18487530
    [No Abstract]   [Full Text] [Related]  

  • 56. [Nephrogenic systemic fibrosis--a new interdisciplinary challenge].
    Witzke O; Hillen U; Barkhausen J; Daul A; Kribben A
    Dtsch Med Wochenschr; 2007 Dec; 132(50):2706-10. PubMed ID: 18058663
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Indirect MR lymphangiography of the head and neck using conventional gadolinium contrast: a pilot study in humans.
    Loo BW; Draney MT; Sivanandan R; Ruehm SG; Pawlicki T; Xing L; Herfkens RJ; Le QT
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):462-8. PubMed ID: 16965993
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tolerability of gadobenate dimeglumine in a patient with reported allergy to gadoterate meglumine.
    Moulin C; Said BB; Berard F
    AJR Am J Roentgenol; 2011 Dec; 197(6):W1163. PubMed ID: 22109336
    [No Abstract]   [Full Text] [Related]  

  • 60. Clinical utility and safety of MultiHance in magnetic resonance imaging of liver cancer: results of multicenter studies in Europe and the USA.
    Hamm B; Kirchin M; Pirovano G; Spinazzi A
    J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S53-60. PubMed ID: 10608398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.